Role of tristetraprolin phosphorylation in paediatric patients with inflammatory bowel disease

Figure 1 Tristetraprolin, 14-3-3 protein and tumor necrosis factor-α expression in colonic mucosa of paediatric inflammatory bowel disease patients. A: Tristetraprolin (TTP) immunoprecipitated, 14-3-3 co-immunoprecipitated expressions in inflamed and non-inflamed frozen colonic inflammatory bowel disease (IBD) tissues were calculated with respect to actin as loading control. Parametric t-test, TTP ^aP < 0.05; B: Representative image of immunoblot experiments; C: Tumor necrosis factor-α (TNF-α) gene expression in inflamed and non-inflamed frozen colonic IBD tissues was calculated with respect to ribosomal protein lateral stalk subunit P0 (RPLP0) and expressed as Log2 of relative expression (RE) of ΔCt. Parametric t-test, TNF-α ^aP < 0.05. IP: Immunoprecipitated; Co-IP: Co-immunoprecipitated; Inf: Inflamed; Non-Inf: Non-inflamed; TTP: Tristetraprolin; IBD: Inflammatory bowel disease; ACT: Actin.

Figure 2 Tristetraprolin, 14-3-3 protein and tumor necrosis factor-α expression in macrophages of paediatric inflammatory bowel disease patients and healthy donors. A: Tristetraprolin (TTP) immunoprecipitated, 14-3-3 co-immunoprecipitated and tumor necrosis factor-α expressions were normalized with actin (ACT) used as loading control. Mann–Whitney test TTP ^aP < 0.05, 14-3-3 ^aP < 0.05; B: Representative image of immunoblot experiments. IBD: Inflammatory bowel disease; HD: Healthy donors; TTP: Tristetraprolin; IP: Immunoprecipitated; Co-IP; Co-immunoprecipitated; TNF-α: Tumor necrosis factor-α; ACT: Actin.